vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与PennyMac Mortgage Investment Trust（PMT）财务数据对比。点击上方公司名可切换其他公司
PennyMac Mortgage Investment Trust的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.2倍（$93.6M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -13.3%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 12.3%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
PennyMac Mortgage Investment Trust是总部位于美国的房地产投资信托，专注于住宅抵押贷款相关资产，主要投资履约及违约抵押贷款、住宅抵押贷款支持证券和信用风险转移工具，业务覆盖美国住房市场的投资管理与抵押贷款服务板块。
PBYI vs PMT — 直观对比
营收规模更大
PMT
是对方的1.2倍
$75.5M
营收增速更快
PBYI
高出41.0%
-13.3%
两年增速更快
PBYI
近两年复合增速
12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $93.6M |
| 净利润 | — | $52.4M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 38.6% |
| 净利率 | — | 56.0% |
| 营收同比 | 27.7% | -13.3% |
| 净利润同比 | — | 12.5% |
| 每股收益（稀释后） | $0.26 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIPMT
| Q4 25 | $75.5M | $93.6M | ||
| Q3 25 | $54.5M | $99.2M | ||
| Q2 25 | $52.4M | $70.2M | ||
| Q1 25 | $46.0M | $44.5M | ||
| Q4 24 | $59.1M | $107.9M | ||
| Q3 24 | $80.5M | $80.9M | ||
| Q2 24 | $47.1M | $71.2M | ||
| Q1 24 | $43.8M | $74.2M |
净利润PBYIPMT
| Q4 25 | — | $52.4M | ||
| Q3 25 | $8.8M | $58.3M | ||
| Q2 25 | $5.9M | $7.5M | ||
| Q1 25 | $3.0M | $9.7M | ||
| Q4 24 | — | $46.5M | ||
| Q3 24 | $20.3M | $41.4M | ||
| Q2 24 | $-4.5M | $25.4M | ||
| Q1 24 | $-4.8M | $47.6M |
毛利率PBYIPMT
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIPMT
| Q4 25 | 22.7% | 38.6% | ||
| Q3 25 | 17.6% | 47.4% | ||
| Q2 25 | 12.7% | 24.2% | ||
| Q1 25 | 8.7% | -14.2% | ||
| Q4 24 | 22.6% | 51.1% | ||
| Q3 24 | 27.4% | 32.8% | ||
| Q2 24 | -4.6% | 40.2% | ||
| Q1 24 | -5.3% | 43.6% |
净利率PBYIPMT
| Q4 25 | — | 56.0% | ||
| Q3 25 | 16.2% | 58.7% | ||
| Q2 25 | 11.2% | 10.7% | ||
| Q1 25 | 6.5% | 21.8% | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | 25.2% | 51.2% | ||
| Q2 24 | -9.6% | 35.7% | ||
| Q1 24 | -11.0% | 64.2% |
每股收益（稀释后）PBYIPMT
| Q4 25 | $0.26 | $0.49 | ||
| Q3 25 | $0.17 | $0.55 | ||
| Q2 25 | $0.12 | $-0.04 | ||
| Q1 25 | $0.06 | $-0.01 | ||
| Q4 24 | $0.40 | $0.45 | ||
| Q3 24 | $0.41 | $0.36 | ||
| Q2 24 | $-0.09 | $0.17 | ||
| Q1 24 | $-0.10 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $190.5M |
| 总债务越低越好 | $22.7M | $1.1B |
| 股东权益账面价值 | $130.3M | $1.9B |
| 总资产 | $216.3M | $21.3B |
| 负债/权益比越低杠杆越低 | 0.17× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资PBYIPMT
| Q4 25 | $97.5M | $190.5M | ||
| Q3 25 | $94.4M | $181.0M | ||
| Q2 25 | $96.0M | $108.6M | ||
| Q1 25 | $93.2M | $204.2M | ||
| Q4 24 | $101.0M | $103.2M | ||
| Q3 24 | $96.7M | $102.8M | ||
| Q2 24 | $96.8M | $336.3M | ||
| Q1 24 | $107.2M | $343.3M |
总债务PBYIPMT
| Q4 25 | $22.7M | $1.1B | ||
| Q3 25 | $34.0M | $299.0M | ||
| Q2 25 | $45.3M | $1.2B | ||
| Q1 25 | $56.7M | $968.4M | ||
| Q4 24 | $68.0M | $1.0B | ||
| Q3 24 | $79.3M | $5.2B | ||
| Q2 24 | $90.7M | $5.4B | ||
| Q1 24 | $102.0M | $5.1B |
股东权益PBYIPMT
| Q4 25 | $130.3M | $1.9B | ||
| Q3 25 | $115.3M | $1.9B | ||
| Q2 25 | $104.7M | $1.9B | ||
| Q1 25 | $97.1M | $1.9B | ||
| Q4 24 | $92.1M | $1.9B | ||
| Q3 24 | $71.1M | $1.9B | ||
| Q2 24 | $48.5M | $1.9B | ||
| Q1 24 | $51.0M | $2.0B |
总资产PBYIPMT
| Q4 25 | $216.3M | $21.3B | ||
| Q3 25 | $202.9M | $18.5B | ||
| Q2 25 | $194.9M | $16.8B | ||
| Q1 25 | $196.2M | $14.9B | ||
| Q4 24 | $213.3M | $14.4B | ||
| Q3 24 | $220.7M | $13.1B | ||
| Q2 24 | $205.0M | $12.1B | ||
| Q1 24 | $214.1M | $12.3B |
负债/权益比PBYIPMT
| Q4 25 | 0.17× | 0.58× | ||
| Q3 25 | 0.30× | 0.16× | ||
| Q2 25 | 0.43× | 0.65× | ||
| Q1 25 | 0.58× | 0.51× | ||
| Q4 24 | 0.74× | 0.52× | ||
| Q3 24 | 1.12× | 2.70× | ||
| Q2 24 | 1.87× | 2.76× | ||
| Q1 24 | 2.00× | 2.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $-7.2B |
| 自由现金流经营现金流 - 资本支出 | $14.4M | — |
| 自由现金流率自由现金流/营收 | 19.1% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | -137.76× |
| 过去12个月自由现金流最近4个季度 | $41.7M | — |
8季度趋势，按日历期对齐
经营现金流PBYIPMT
| Q4 25 | $14.4M | $-7.2B | ||
| Q3 25 | $9.7M | $-1.3B | ||
| Q2 25 | $14.1M | $-2.0B | ||
| Q1 25 | $3.6M | $-594.3M | ||
| Q4 24 | $15.6M | $-2.7B | ||
| Q3 24 | $11.0M | $-983.8M | ||
| Q2 24 | $1.0M | $243.8M | ||
| Q1 24 | $11.2M | $-342.4M |
自由现金流PBYIPMT
| Q4 25 | $14.4M | — | ||
| Q3 25 | $9.7M | — | ||
| Q2 25 | $14.1M | — | ||
| Q1 25 | $3.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $1.0M | — | ||
| Q1 24 | — | — |
自由现金流率PBYIPMT
| Q4 25 | 19.1% | — | ||
| Q3 25 | 17.7% | — | ||
| Q2 25 | 26.8% | — | ||
| Q1 25 | 7.7% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
资本支出强度PBYIPMT
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率PBYIPMT
| Q4 25 | — | -137.76× | ||
| Q3 25 | 1.10× | -22.26× | ||
| Q2 25 | 2.41× | -267.53× | ||
| Q1 25 | 1.21× | -61.39× | ||
| Q4 24 | — | -58.08× | ||
| Q3 24 | 0.54× | -23.76× | ||
| Q2 24 | — | 9.59× | ||
| Q1 24 | — | -7.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
